KOSPIBiotech & Pharma950210

Prestige BioPharma

₩3,710▼ 1.07%2026-11-18 close
Market Cap
₩223B
Turnover
₩100M
Volume
30K
Shares out.
60.1M
PER
—
PBR
0.6×
EPS
-₩1,412
Dividend Yield
—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Prices as of the 2026-11-18 close

01

Report overview

Revenue Up Three Straight Years, Losses Still Widening

Prestige BioPharma's revenue rose for a third straight year to KRW 24.2 billion (converted) in the fiscal year ended June 2026, but operating losses widened to KRW 86.8 billion, which makes the pace of profitability improvement the key point to watch.

  1. 1

    Revenue for the fiscal year ended June 2026 was KRW 24.2 billion (converted), up 76.1% from the prior year, and has grown for three consecutive fiscal years since the year ended June 2024.

  2. 2

    The operating loss widened to KRW 86.8 billion, and the company has posted operating losses for four consecutive fiscal years starting with the year ended June 2023.

  3. 3

    Q2 2026 revenue jumped to KRW 14.2 billion (converted), yet the quarter still recorded an operating loss of KRW 20.8 billion and a net loss attributable to controlling shareholders of KRW 39.3 billion.

  4. 4

    On the pipeline side, the company targets entering a Phase 2a trial for the pancreatic cancer antibody PBP1510 within 2026, while the trastuzumab biosimilar TUZNUE (HD201) holds European Union marketing authorization.

  5. 5

    Total equity at the end of June 2026 was KRW 440 billion (converted), mostly attributable to controlling shareholders, and the debt-to-equity ratio eased to 46.2% from 46.7% in the prior fiscal year.

02

Business structure

Prestige BioPharma is a pharmaceutical company developing antibody medicines, pursuing biosimilars, antibody new drugs and diagnostic technology in parallel. Its lead biosimilar is TUZNUE (HD201), a trastuzumab biosimilar and the first commercial pipeline to receive European Commission marketing authorization.

The company says it signed a license and supply agreement with Teva covering 31 European markets and has since recorded marketing approvals in Brazil and the Caribbean. VASFORDA (HD204), a bevacizumab biosimilar, is in preparation for North American approval and commercialization.

In antibody drugs, the pancreatic cancer candidate PBP1510 is preparing to enter a Phase 2a trial based on Phase 1 data, while PBP1710, aimed at solid tumors, is in development as a national new-drug research project.

On diagnostics, the company promotes TASA, a blood-based early detection technology for pancreatic cancer that measures PAUF.

Manufacturing is handled by Prestige Biologics, a consolidated subsidiary, and the company cited milestone income, drug substance sales and that subsidiary's contract manufacturing sales as drivers of fiscal 2026 revenue.

Its research subsidiary IDC signed an MOU on November 10, 2026 with an AI drug-discovery firm for joint antibody research. Among listed peers, Celltrion and Samsung Biologics are the main reference points in biosimilars and CDMO, while Alteogen is a comparison point for antibody formulation technology.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q2₩5.3B-₩13.7B−258.8%
2025Q3₩2.2B-₩23.6B−1051.6%
2025Q4₩7.3B-₩17.7B−242.4%
2026Q1₩500M-₩24.7B−5175.1%
2026Q2₩14.2B-₩20.8B−147.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023.06₩200M-₩70.8B₩17.9B−42988.4%3.9%35.8%
2024.06₩700M-₩63.4B-₩33.2B−9111.2%−7.8%38.1%
2025.06₩13.7B-₩64.6B₩21.4B−470.1%5.2%46.7%
2026.06₩24.2B-₩86.8B-₩84.9B−359.1%−22.5%46.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-10

04

Earnings analysis

On a disclosed annual basis, revenue rose from KRW 165 million (converted) in the fiscal year ended June 2023 to KRW 24.2 billion in the year ended June 2026, growing for three consecutive fiscal years since the year ended June 2024.

The year ended June 2026 is the largest year in the period from June 2023 to June 2026. The sharp increase in the year ended June 2025 was reported to reflect wider recognition of milestone income following the European marketing authorization for TUZNUE, and growth slowed to 76.1% in the year ended June 2026.

Over the same span, operating losses were KRW 70.8 billion, KRW 63.4 billion, KRW 64.6 billion and KRW 86.8 billion, marking four consecutive fiscal years of operating losses, with the largest loss in the year ended June 2026.

Cost of sales rose 52.2% year on year and R&D expenses more than doubled, and a report based on the business report read this as revenue growth failing to keep pace with costs (Junggi Economy).

The operating margin improved to -359.1% from -9,111.2% and -470.1% in the two prior years, but losses remain large relative to sales. Net income attributable to controlling shareholders swung from a KRW 21.4 billion profit in the year ended June 2025 back to a net loss of KRW 84.9 billion in the year ended June 2026.

Net loss including non-controlling interests was KRW 114 billion in the latest year, with the report citing higher other expenses and finance costs as the main drivers. Operating cash flow was negative in all four years, at -KRW 61.3 billion, -KRW 48.5 billion, -KRW 50 billion and -KRW 51.8 billion.

Quarterly revenue swung widely, from KRW 5.3 billion in Q2 2025 to KRW 2.24 billion in Q3, KRW 7.31 billion in Q4, KRW 478 million in Q1 2026 and KRW 14.2 billion in Q2 2026, all converted from USD.

The net loss attributable to controlling shareholders of KRW 39.3 billion in Q2 2026 was the largest quarterly figure in the disclosed period, and the four quarters from Q3 2025 to Q2 2026 total KRW 84.9 billion in net losses attributable to controlling shareholders.

05

Industry analysis

The market Prestige BioPharma operates in is the commercialization stage of biosimilars and antibody medicines, where securing distribution and sales partners after approval determines how fast revenue grows.

On the trastuzumab biosimilar market, an industry source was reported to put the European market at roughly KRW 5 trillion, with biosimilars already holding more than half of it (Eindaily report).

The company has extended TUZNUE's European sales through its Teva agreement and is seeking new partners in regions it has not yet entered. The same report pointed to price competitiveness as the key variable for late entrants, and the company says its in-house development capabilities keep its cost structure low.

In biosimilar commercialization, outcomes depend more on approval, tender and partner execution for each product than on the broader industry cycle.

Among listed peers, Celltrion and Samsung Biologics anchor the biosimilar and CDMO comparison, while Alteogen is cited in antibody competition for its subcutaneous formulation technology.

Pancreatic cancer is an area with limited treatment options, and global interest has risen, with PBP1510 presented at ASCO and ESMO GI on its PAUF-targeting strategy. Antibody drug candidates depend heavily on clinical results and partnership terms, which gives them a different earnings profile from biosimilars.

06

Outlook

The near-term agenda the company has disclosed centers on North American market entry and the clinical advance of its antibody pipeline.

VASFORDA is in preparation for North American approval and commercialization, and Prestige Biologics, which handles production, is upgrading its manufacturing and quality systems to meet inspections and review by global regulators.

For TUZNUE, the company is negotiating with a potential North American partner on business structure and division of roles. PBP1510 is evaluating Phase 1 data and targets entry into a Phase 2a trial within 2026.

At ESMO GI 2026 in July, the company shared its Phase 2a development direction and PAUF-targeted treatment strategy. PBP1710, aimed at solid tumors, is under discussion for joint development and technology transfer with global pharma companies.

At CPHI Milan 2026 in October, the company aimed to identify new commercialization partners for TUZNUE in regions where it is not yet sold. The joint antibody research with an AI drug-discovery firm, announced on November 10, 2026 through IDC, starts with a pilot study and is designed to widen cooperation over time.

The company also presents its subcutaneous formulation conversion technology for antibody drugs and AI-based R&D capabilities, so how these technologies are applied at the commercial stage is the next point to watch.

07

Valuation

PER
—
PBR
0.6×
ROE
-22.5%
EPS
-₩1,412
BPS
₩6,272
Dividend per share
—

Prestige BioPharma has posted net losses over the last four quarters, so an earnings-based multiple comparison does not apply. On an asset basis, the price-to-book ratio sits in a low range, with the stock trading below net asset value.

Of total equity of KRW 440 billion (converted), most is attributable to controlling shareholders, and the debt-to-equity ratio of 46.2% is slightly lower than in the year ended June 2025.

The realizable value of book assets, however, depends on how the pipeline performs in commercialization and clinical trials, so price relative to net assets should be read together with the recoverability of R&D assets.

On the multi-year trend, the company swung to a profit in the year ended June 2025 and then back to a loss in the year ended June 2026.

A 2024 investor briefing reportedly set a target of KRW 300 billion in annual revenue for 2026, while revenue in the year ended June 2026 was KRW 24.2 billion (converted), a wide gap from that target. Valuation discussion therefore centers on the pace of revenue expansion and the timing of narrowing operating losses.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-10

08

Bull factors

Three Years of Revenue Growth

Revenue has grown for three consecutive fiscal years through the year ended June 2026, reaching KRW 24.2 billion (converted) with a 76.1% increase over the prior year. Q2 2026 revenue of KRW 14.2 billion (converted) was well above the prior quarter, lifting quarterly scale.

The cited drivers of milestone income, drug substance sales and contract manufacturing sales allow the reading that commercial results are beginning to show up in reported figures.

EU-Approved Pipeline and Wider Partnering

TUZNUE holds European Union marketing authorization, and the company has reported a license and supply agreement with Teva covering 31 European markets along with approvals in Brazil and the Caribbean.

The company pursued North American and new regional partnerships at BIO USA in June 2026 and CPHI Milan in October 2026. An MOU for joint antibody research between IDC and an AI drug-discovery firm, signed on November 10, 2026, broadens the development base.

Lower Leverage and Equity Base

Total equity at the end of June 2026 was KRW 440 billion (converted), and the debt-to-equity ratio fell to 46.2% from 46.7% in the year ended June 2025. Total liabilities were KRW 203.5 billion.

While the equity base holds up, the company can run clinical work and North American preparation in parallel, which is read as a financial strength.

09

Bear factors

Four Years of Losses and a Wider Gap

The operating loss was KRW 86.8 billion in the year ended June 2026, marking four consecutive years of operating losses with the widest loss in that year. Net loss attributable to controlling shareholders was KRW 84.9 billion, reversing the profit of the year ended June 2025.

The KRW 39.3 billion net loss attributable to controlling shareholders in Q2 2026 is the largest among five consecutive loss-making quarters.

Costs Growing Faster Than Revenue

According to a Junggi Economy report based on the business report, cost of sales rose 52.2% year on year and R&D expenses more than doubled. Operating cash flow has been negative for four consecutive years through the year ended June 2026, at -KRW 51.8 billion. If cost burdens persist while revenue growth slows, the need for external funding could increase.

A Wide Gap to a Past Revenue Target

A 2024 investor briefing reportedly set a target of KRW 300 billion in annual revenue for 2026. Revenue in the year ended June 2026 was KRW 24.2 billion (converted), a wide gap from that target.

Quarterly revenue has swung sharply as milestone and contract recognition timing shifts, which makes earnings harder to forecast.

10

Risk factors

Clinical and Development Risk

PBP1510 is evaluating Phase 1 data before preparing to enter Phase 2a, and entering that phase within 2026 is the company's target. A delay or results that fall short of expectations would keep R&D costs elevated and could change how the pipeline is valued.

Pancreatic cancer drugs are widely known for high clinical failure rates, so data at each stage carries heavy weight.

Financing Risk

Operating cash flow has been negative for four straight years, and operating losses remain larger than revenue. Equity of KRW 440 billion (converted) at the end of June 2026 is sizable, but if losses persist, whether the company needs additional equity or borrowing becomes a key variable. Because the company reports in US dollars, the won-converted figures are affected by exchange rate moves.

Commercialization and Partner Dependence

A large share of revenue rests on TUZNUE-related milestone income and drug substance sales, so quarterly results could swing widely depending on contract terms and partner execution. The timing at which a North American partner and VASFORDA approval will show up in reported results is uncertain. Whether the Teva supply agreement converts into actual volumes is another point to watch.

11

What to watch next

  1. Around November 14, 2026 (statutory filing deadline)

    This is when the quarterly report for Q3 2026 (July to September) is filed. It will show whether the Q2 2026 revenue of KRW 14.2 billion (converted) is sustained and whether operating and net losses keep trending in the same direction.

  2. By December 31, 2026

    This is the company's target window for entering a Phase 2a trial for PBP1510. Whether the entry happens within 2026 and how the Phase 1 data evaluation is disclosed will indicate the pipeline's progress.

  3. Around February 14, 2027 (statutory filing deadline)

    This is when the periodic report covering October to December 2026 is filed. It will show whether quarterly revenue swings have narrowed and whether the rise in net losses attributable to controlling shareholders has leveled off.

  4. Ad hoc disclosures after November 2026

    These are the selection of a North American partner for TUZNUE and the progress of VASFORDA's North American approval. Once either is confirmed through disclosure or press reports, changes in revenue structure and commercialization scope can be gauged.

12

Overall view

Prestige BioPharma grew revenue for a third straight year to KRW 24.2 billion (converted) in the year ended June 2026, and its debt-to-equity ratio eased slightly from the prior year.

On the other side, operating losses of KRW 86.8 billion and net losses attributable to controlling shareholders of KRW 84.9 billion widened, and operating cash flow has been negative for four years.

Q2 2026 revenue of KRW 14.2 billion (converted) rose sharply on a quarterly basis, but the KRW 39.3 billion net loss attributable to controlling shareholders in the same quarter is the largest quarterly figure in the disclosed period.

On the business side, TUZNUE's European authorization, VASFORDA's North American preparation and the Phase 2a target for PBP1510 are cited as growth grounds.

However, the timing and scale of pipeline revenue have not yet been fully reflected in results, and the gap to the past target of KRW 300 billion in 2026 annual revenue remains wide.

Bullish factors are the revenue growth trend, wider partnering and the size of the equity base, while bearish factors are persistent operating losses, negative cash flow and dependence on clinical and partner outcomes.

The next checkpoints are the operating loss trend in the Q3 2026 quarterly report, due around November 14, 2026, and the PBP1510 Phase 2a entry targeted by the end of December 2026.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. junggi.co.kr
  2. sedaily.com
  3. stardailynews.co.kr
  4. yakup.com
  5. thebionews.net
  6. dailyinvest.kr
  7. pharm.edaily.co.kr
  8. insight.goover.ai
  9. pflow.keywordegg.com
  10. pharm.edaily.co.kr
  11. newspim.com
  12. medipharmhealth.co.kr
  13. newspim.com
  14. thebionews.net
  15. view.asiae.co.kr
  16. m.news.nate.com
  17. v.daum.net
  18. markets.hankyung.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis